Category Archives: Psoriasis

Psoriasis is a common chronic inflammatory skin condition. It can cause red, purple, or grayish patches to develop that are covered in silvery scales. There are numerous types of psoriasis, and knowing which type a person has allows medical professionals to develop a treatment plan. Psoriasis is not contagious.

Psoriasis is a common condition that affects over 8 million people in the United States.

There are a number of types of psoriasis, and they often have similar triggers. These triggers can include:

This article will discuss different types of psoriasis. For each one, it will list symptoms, locations, and treatment options.

Plaque psoriasis is the most common type of psoriasis.

Symptoms of plaque psoriasis include:

On light skin, these plaques appear as raised and red. On dark skin, the patches may be purple, grayish, or darker brown in color.

These plaques become covered in a silvery or white buildup of dead skin cells that medical professionals call scales.

See pictures of plaque psoriasis here.

Plaque psoriasis can appear on most areas of the body. However, it most often develops on the:

Topical treatments for plaque psoriasis include:

Other treatments can include phototherapy, biologics, and systemic medications that a person can take orally or via an injection.

Learn more about plaque psoriasis here.

Approximately 8% of people who have psoriasis develop guttate psoriasis. This type of psoriasis can start at any age, but it most commonly starts at an early age, around childhood and young adulthood.

Infections of streptococcal bacteria cause strep throat, which is the most common cause of guttate psoriasis.

Guttate psoriasis is a distinct type of psoriasis that appears as small round spots called papules. These are raised and are sometimes scaly.

Inflammation of the skin causes the papules to form. They often appear on the:

However, papules may also develop on a persons face, ears, and scalp.

The first line of treatment for mild guttate psoriasis is topical corticosteroids. Other treatment options include phototherapy and oral treatments.

If a persons symptoms persist, a medical professional may recommend the use of a biologic or a combination of treatments.

Learn more about guttate psoriasis here.

Inverse psoriasis, sometimes called intertriginous psoriasis, affects 2130% of people with psoriasis.

Inverse psoriasis has similar triggers to plaque psoriasis, including:

Inverse psoriasis appears as lesions on the body. These lesions are purple or brown on dark skin, and bright red on light skin.

The lesions may also appear smooth and shiny. However, they tend to lack the scaling that people may notice with plaque psoriasis.

This type of psoriasis commonly develops in the folds of the skin. It most often affects the following parts and areas of the body:

Moisture, rubbing, and sweating can all make inverse psoriasis symptoms worse.

Treatment for inverse psoriasis can include:

Learn more about inverse psoriasis here.

Erythrodermic psoriasis is a rare type of psoriasis that is aggressive and can affect the entire body. It can also become very serious and may be life threatening. It affects 12.25% of people with psoriasis.

This type of the condition has the same general triggers as most other types, including medications, skin injuries, allergic reactions, and stress.

Symptoms of this type of psoriasis can be very serious and include:

If a person experiences these symptoms, they should seek emergency medical attention.

Erythrodermic psoriasis disrupts a persons body temperature and fluid balance. This can cause shivering episodes and swelling due to fluid retention.

A person with this type of psoriasis may also be at a higher risk of infection, pneumonia, and heart failure.

Before treating erythrodermic psoriasis, doctors will first ensure a person is stable. They will start by correcting any fluid, protein, or electrolyte imbalance. They will then treat any secondary infections and protect the person against hypothermia.

An individual with this type of psoriasis can also develop sepsis, which can become fatal, so doctors will treat this immediately if it is present.

Once a persons condition is stable, doctors can treat the erythrodermic psoriasis. They do this using a number of medications, such as cyclosporine, infliximab, methotrexate, or acitretin.

Other treatment options may include topical treatments and biologics that can work alongside the medications described above.

Learn more about erythrodermic psoriasis here.

There are different types of pustular psoriasis, and medical experts categorize them based on where the symptoms appear.

Pustular psoriasis appears as pus-filled bumps called pustules. These pustules might be surrounded by inflamed, discolored skin.

Generalized pustular psoriasis (GPP) causes widespread pustules to appear in large numbers across large areas of the body.

GPP can develop quickly and can be very serious. Its symptoms can also include fever, chills, severe itching, fatigue, a change in heart rate, and muscle weakness.

If a person suspects they have GPP, they should contact a medical professional right away.

Localized pustular psoriasis, also known as palmoplantar pustular psoriasis, tends to affect the palms of the hands and the soles of the feet.

Acropustulosis affects only the tips of the fingers and the toes. This is very rare and may come after an injury or infection.

Learn more about palmoplantar psoriasis here.

Medical professionals will treat this condition with one of the following:

Learn more about pustular psoriasis here.

Nail psoriasis affects the fingernails and toenails. It causes changes in them that can lead to discoloration or alterations in the nail bed.

Common symptoms of nail psoriasis include:

Treatment options for nail psoriasis include:

Learn more about nail psoriasis here.

Psoriatic arthritis is a chronic autoimmune condition that causes the joints to become inflamed. It often occurs with another form of psoriasis.

It can start at any age. However, it most commonly occurs in people aged 3050 years.

Symptoms of psoriatic arthritis include:

This condition can affect small or large joints. In some rarer instances, it can affect the spine.

Early, aggressive treatment can improve the quality of life of a person with psoriatic arthritis. A person with this condition may need to seek treatment from a primary care doctor, a dermatologist, and a rheumatologist.

Treatment for psoriatic arthritis can include oral medications that reduce inflammation and swelling.

A doctor may also use biologics to target specific parts of the immune system to combat symptoms and slow joint damage.

Learn more about psoriatic arthritis here.

Psoriasis is a common skin condition that causes colored patches of skin to develop. These patches can be red, purple, or grayish, depending on a persons skin tone. They can also be covered in scales and become itchy and may cause a burning sensation to develop.

There are various types of psoriasis, all of which produce differing symptoms.

Psoriasis can develop all over the body and can affect the scalp, knees, elbows, torso, genitals, face, hands, feet, or fingernails.

There are numerous treatments for psoriasis, including topical treatments, phototherapy, biologics, and systemic medications.

A person should contact a primary care doctor or dermatologist if they suspect they have psoriasis.

Read the original here:
Types of psoriasis: Pictures, locations, and more - Medical News Today

GC Lab Cell said Thursday that it has won the Ministry of Food and Drug Safetys approval for phase 1 clinical trial of CT303, a candidate substance of stem cell therapy for psoriasis.

The company submitted an investigational new drug (IND) application for the trial in June.

The trial is designed to analyze the safety, and drug tolerance of repetitive single dose administers of CT303 (human tonsil-derived mesenchymal stem cell) on 24 moderate-to-severe plaque psoriasis (PsO) patients. It will proceed at multiple institutions with an increasing quantity. The institutions include Seoul National University Hospital, Pusan National University Hospital, CHA University, and CHA Bundang Medical Center.

Psoriasis, a chronic inflammatory autoimmune disease, has a prevalence rate of 3 percent worldwide. About 1.5 million Koreans are estimated to have the condition. Because of the shape or formation of the lesions, it considerably affects patients' lives, causing emotional difficulties.

GC Lab Cell said CT303 was manufactured using tonsil-derived tissue from healthy donors aged below 10 years. By controlling the excessive immune reaction, it helps improve psoriasis symptoms.

CT303 is an advanced platform technology that has maximized anti-inflammatory effects compared to preexisting mesenchymal stem cell therapies. We can also develop additional indications treating other inflammatory diseases, said Hwang Yu-kyung, director of GC Lab Cells Cell Therapy Research Center.

GC Lab Cell CEO Park Dae-woo also said, As we have focused on developing a differentiated stem cell therapy with natural killer cell therapies, beginning with psoriasis treatment, we will enter additional clinical trials for autoimmune disease or acute inflammatory disease treatment by the second half of the year.

GC Lab Cell has researched the massive production, subculture, and freezing of tonsil-derived stem cells using NK cell therapy know-how. The company has developed tonsil-derived stem cells with strengthened anti-inflammatory abilities proven for their effects on the regenerating tissues and reducing the cause of psoriasis through animal model experiments, the company said.

Read the original here:
GC wins regulatory nod for trials of psoriasis therapy - Korea Biomedical Review

Psoriasisis a condition that directly affects the human skin. The condition is a long-term disease that currently has very few or no treatment options. The severity of the illness and inadequate treatment methods will lead to a high emphasis on early detection and treatment of the disease worldwide. The increasing research and development activities and increased investments in these activities will create several growth opportunities for the companies working in the market.

DelveInsightsPsoriasis Pipeline Insight, 2021,report provides comprehensive insights about80+ companies and 80+ pipeline drugsin the Psoriasis pipeline landscape. The report covers the pipeline drug profiles, including clinical & non-clinical stage products.Psoriasis Pipeline Insightalso covers the therapeutics assessment by stage, product type, route of administration, & molecule type. The report further highlights the inactive pipeline products in this space.

Some of the Psoriasis companies:

Request for Sample Report:https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

Psoriasis Symptoms include red patches, itchiness, rashes, and irritation. The increasing medical activities associated with the condition and the growing emphasis on the development of efficient treatment options will emerge in favor of the growth of the overall psoriasis treatment market in the foreseeable future.

Psoriasis Types

Some Psoriasis Therapies are:

Scope ofPsoriasis Pipeline Drug Insight

Request for Sample Report:https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

Table of Contents:

Introduction

Executive Summary

Psoriasis: Overview

Pipeline Therapeutics

Therapeutic Assessment

Psoriasis DelveInsights Analytical Perspective

In-depth Commercial Assessment

Psoriasis Collaboration Deals

Late Stage Products (Phase III)

CT-P43: Celltrion

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

EDP1815: Evelo Biosciences

Drug profiles in the detailed report..

Early Stage Products (Phase I)

AZD0284: AstraZeneca

Drug profiles in the detailed report..

Early Stage Products (Preclinical)

AZD0284: AstraZeneca

Drug profiles in the detailed report..

Inactive Products

Psoriasis Key Companies

Psoriasis Key Products

Psoriasis- Unmet Needs

Psoriasis- Market Drivers and Barriers

Psoriasis- Future Perspectives and Conclusion

Psoriasis Analyst Views

Psoriasis Key Companies

Appendix

About Delveinsight :

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platformPharmDelve.

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address: 304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight

Continue reading here:
Psoriasis Pipeline: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Developments and Companies by DelveInsight -...

Many of the most common sexually transmitted diseases (STDs) are typically identified by a handful of common symptoms. Herpes, for example, frequently causes genital warts and bumps around the mouth or genitals.

But sometimes, STDs cause less obvious and lesser-known symptoms. One of these often unrecognized symptoms is dry skin. Indeed, dry skin may be one sign that you have an STD.

Frequently, STD is used interchangeably with the term sexually transmitted infection (STI), but theyre different. STIs are infections that can develop into STDs. As an example, human papillomavirus (HPV) is an STI, unless it leads to genital warts or cervical cancer, which are STDs.

In this article, well primarily discuss dry skin thats caused by STDs. Well also look at some key STIs and their connection to dry skin.

Dry skin is a common symptom of a number of conditions, from allergies and psoriasis to STDs. Any patch of dry skin you develop isnt necessarily a sign you have an STD, but if you have other symptoms, its worth making an appointment with your healthcare professional to have a full STD screening.

Lets review the STDs that can cause dry skin as well as other symptoms these STDs cause so you can spot them when or if they occur.

Herpes is an STD caused by a herpes simplex virus (HSV) infection. Two types of HSV exist, and each can cause lesions or warts along the mouth or genitals. They can also cause:

Whats more, people with herpes are at higher risk for developing eczema herpeticum. This is a type of serious skin infection that can be deadly if not treated properly.

Symptoms of this condition include burning, tingling, and itching skin. It commonly occurs along the neck and head, but it can occur anywhere on the body. It also is most likely to occur 5 to 12 days after contact with a person who has HSV.

Syphilis is an STD caused by the bacterium Treponema pallidum. In the secondary phase of the infection, about 3 to 6 weeks after contracting the infection, its not uncommon to develop dry, scaly rashes on the body. Theyre more common on the palms of your hands or the soles of your feet, and theyre unlikely to itch.

In addition to dry skin, people in this second phase of infection may also experience sore throat, fever, and symptoms that resemble the flu.

Genital warts are an STD caused by HPV. In addition to skin-colored bumps that frequently develop around the genitals or anus, HPV can cause dry, itchy skin. The warts themselves can be dry and itchy, as well as the skin around the warts. Additionally, skin elsewhere on the body could become dry as a result of the infection.

AIDS is an STD that can develop if you contract HIV. Over time, HIV can damage and weaken the immune system. This can cause the virus symptoms to worsen. As the immune system weakens, additional symptoms of an HIV infection or AIDS develop. Skin symptoms, including dry skin and rash, can be one of these symptoms.

The STIs that are responsible for some of the most common STDs can cause symptoms like dry skin. These STIs include:

Dry skin on or near the groin isnt always a sign of an STI or STD. It can be an indication of a number of other potential diseases or conditions. These include:

If youve developed persistent dry skin that doesnt improve with over-the-counter moisturizers like body lotions, you should consider scheduling an appointment with a medical professional. While many causes of dry skin have nothing to do with STDs or STIs, some do. In those cases, its a good idea to diagnose and begin any treatments so that youre not at risk for complications.

People who are sexually active with multiple partners should consider STD screenings one to two times a year. You may also want to consider a screening before entering a new relationship.

Many of the most common STIs and STDs dont cause symptoms until the disease is advanced. Knowing before you reach that point can help you treat and be prepared to avoid passing the STD to a partner.

Dry skin can occur anywhere on the body, and its often the result of issues like allergies, inflammation, or skin irritation. But dry skin in the groin may set off a different set of alarm bells. Thats because dry skin can be a sign of an STD.

If you can recognize the signs and symptoms of STDs, including uncommon ones like dry skin, you can begin treatment right away. Regular STD screening is also a good idea.

Excerpt from:
STDs that Cause Dry Skin: Types and their Treatments - Healthline

(WYTV) So you have a few extra skin cells on your body what harm can that do? Actually, it can do a lot.

Psoriasis, a disease that affects more than 3% of the adult population in the U.S., is brought on by an overproduction of skin cells and can range from mild to severe.

Psoriasis is an inflammatory skin disease that leads to a rash on the skin. It most commonly affects the elbows and the knees, but can really occur anywhere, like the scalp, or the hands or even the genitals, said Dr. Melissa Piliang, with the Cleveland Clinic. The rash is usually pink with thick scale. It may be that you feel like you trail scale when you walk around your house.

Some patients go in for ultraviolet light therapy, or several different medications and treatments.

Psoriasis can affect a persons health in other ways, too. It can lead to a higher risk for heart disease and diabetes, hypertension and high cholesterol.

Theres no cure for psoriasis, but researchers are always looking into different treatments and how diet and lifestyle play a role.

See the original post here:
Psoriasis affects more than just the skin - WYTV

Psoriatic arthritis (PsA) is a chronic condition that occurs in people with psoriasis. Psoriasis is an inflammatory disease that affects the skin and nails and can also affect the joints. Finger PsA may cause pain and swelling in one or more finger joints.

In most cases, psoriasis occurs in early adulthood, with one-third of people going on to develop PsA after the age of 30. A milder form of psoriasis can also develop later in life, but typically, this form does not cause arthritis.

Once PsA develops, it can start to damage the bones after a few months, so it is important to seek medical advice and treatment for the condition.

In this article, we will look at PsA in the fingers, including the symptoms, treatment, and management.

It is common for PsA to affect smaller joints, such as those in the fingers. Often, the condition affects the joint closest to the nails.

People who develop PsA in the fingers may experience:

PsA typically affects joints asymmetrically, which means it may develop in one hand and not the other. The symptoms can range from mild to severe and may progress, decrease, or remain the same for long periods of time.

The condition often affects the area of the hands closest to the nails, causing swelling that resembles gout.

In the later stages of PsA, the spaces between joints may narrow or completely disappear due to a loss of cartilage.

Yes, people can have PsA symptoms in just one finger, or just in one hand, according to the Arthritis Foundation.

PsA affects everyone differently. Doctors are not sure what causes it or why some people with psoriasis develop joint problems where others do not.

However, it is likely that a combination of genetic and environmental factors plays a role.

Trigger finger, also known as tenosynovitis, occurs when a pulley in the hand becomes inflamed. Each finger has a sheath, or tunnel, of tissue that acts like a pulley, holding tendons in place as they move. If this part of the finger thickens, the finger will become stuck in a bent position.

Tenosynovitis can occur in many places around the body, but it most frequently occurs in the hands, wrists, and feet.

A 2018 study suggests that in people with PsA, these pulleys are thickened, which could result in PsA-related trigger finger.

However, trigger finger does have other causes, including infections. Sometimes, infections that cause the condition are serious and spread quickly.

That is why it is important to seek guidance from a doctor if a person develops trigger finger, especially if redness and swelling are present.

When diagnosing PsA in the fingers, doctors will begin by taking a medical history.

If an individual already has psoriasis or if their family has a history of the condition, this may help determine the cause of finger pain and swelling.

Next, doctors may examine the hand. They will look for:

Doctors may also order imaging tests, such as radiography, ultrasonography, and MRI scans.

Treatment for PsA may entail:

Doctors choose treatments based on the severity of a persons symptoms. Some people may only need NSAIDs or to take medications during flare-ups, while those with more advanced PsA may need more intensive treatment.

In some cases, surgery may be necessary to address damage.

Not all of these drugs are suitable for everyone. That is why doctors will take into account any other medical conditions a person has, any medications they are taking, their individual response to different treatments, and risk of side effects.

Living with PsA can be challenging, particularly if it inhibits movement in the hands.

People can look after the health of their joints and manage the symptoms of PsA by trying:

It is important to look after the health of other joints in the body, even if they have not become affected by pain and swelling. Regular low-impact exercise, such as walking or swimming, can improve health without placing strain on the joints.

It is also advisable to protect the skin if a person has psoriasis on the affected joint. People can do this by:

If a person struggles to move their finger much or if PsA affects multiple joints, they may benefit from consulting an occupational therapist. These are medical professionals who can help a person adapt their home and learn how to use assistive devices so that everyday tasks become easier.

Learn more about occupational therapy here.

There are other conditions that can cause symptoms similar to those of PsA. If a person does not have psoriasis, the cause of finger swelling may be something else.

Some examples of conditions that could result in finger joint inflammation include:

If a person suspects they have psoriasis or PsA, they should contact a doctor for diagnosis and treatment as soon as they can.

Without treatment, the symptoms may continue or get worse over time. PsA can also cause damage to bones, which is irreversible.

Additionally, people should seek guidance from a doctor if they have any other unexplained symptoms, such as:

These could be signs of other conditions that resemble PsA.

Finger PsA causes pain and swelling in the finger joints. It can affect just one finger or one hand. While PsA occurs in people with psoriasis, doctors do not know the exact cause of the condition.

Doctors can diagnose PsA with the help of physical examination and diagnostic and medical imaging tests.

Treatment can depend on how severe the symptoms are but may include a combination of medications and diet or lifestyle changes.

Read more from the original source:
Finger psoriatic arthritis: Symptoms, pictures, and coping tips - Medical News Today

Living with psoriasis, a chronic autoimmune disease, is a roller coaster, Tikeyah, a 30-year-old woman with psoriasis, told Glamour. The unpredictable skin condition causes inflammation in the body that sometimes shows up as red patches with silvery scales on topfrequently on the knees, elbows, and scalp, though they can appear anywhere.

But Tikeyah has found ways to feel confident while living with psoriasisand so have millions of women like her, no matter what their skin looks and feels like on any given day. Scroll down for their tips.

Psoriasis can feel debilitating at times. To make myself more comfortable, I try to wear loose-fitting cotton clothes whenever Im home, and I opt out of wearing underwear whenever possible. When nothing is rubbing against my inflamed skin, I feel more confident and relaxed, and I can spend more quality time with my family. Masha, 30, California

From my experience, most people react negatively to my skin condition because theyre afraid its contagious. I wont go around telling everyone that I have psoriasis. But when my flare-ups are visible at work, I let my company know. It may sound weird, but getting it out of the way up front usually saves me a lot of troubleand a lot of worried side glances or carefully crafted questionslater on. It may be frustrating, but I remind myself that people are hardwired to shrink away from things that they arent familiar with. Jill, 50, British Columbia

Take your experience and make the best of it. I dont mean to come off as blas: I understand the struggleboth internally and externallythat people go through with psoriasis. But when you get through the muck of it, take time to be kind to yourself. No matter what you look like or feel like, this is your bodyand its your only one. Learn to love yourself. Find ways to reach deep down and build that relationship with yourself. If you feel negatively, its okay to get help. I did and still do. Its a constant struggle but its very worth loving yourself. Brittany, 35, New York

One of the frequent, potentially embarrassing situations I used to run into was hair appointments. I would always cringe when I first sat down in the chair because I have dry, flaky patches on my scalp. Now I tell anyone who is going to come into contact with my scalpwhether for a scalp massage or shampooingthat I have this condition, I was born with it, and it wont harm them in any way. I think the more we can own who we are, the better we can feel about ourselves. Sarah, 37, California

For special occasions, I like to splurge on a professional spray tan. There is something about golden, sun-kissed skin that brings on that extra boost of confidence for summer weddings and celebrations. Bianca, 34, California

Living with psoriasis is a roller coaster. But you can build confidence by taking control however you canwhether thats picking outfits that make you feel pretty, or changing your hairstyle if you have scalp psoriasis. Whatever it is, do it. Psoriasis is an unpredictable autoimmune disease, so its easy to feel like its controlling your every move. But finding ways to take control of what parts of my skin I choose to show has proven to be so helpful for me. Tikeyah, 27, Georgia

If you have a job interview or a social occasion that calls for an outfit that will reveal a flare-up, try using a natural concealer without fragrances or alcohol to minimize any redness. I like to use concealers that have jojoba seed oil to reduce inflammation and redness on my legs. Kristin, 40, New York

Find a personal mantra that supports how youd like to feel, then practice it until you find peace and feel confident. I write my mantra on my bathroom mirror so I can see it. You begin to love the skin youre in by accepting yourself in a positive light. Patrice, 34, North Carolina

Recently my family moved to the beach permanently, and its taken some getting used tomy psoriasis gets in the way of me feeling comfortable. Teeny bikinis are on trend, but theyre not for me. Buy a bathing suit that you feel most comfortable in. Its important to feel your best when you are at the beach, and a less-revealing bathing suit makes me feel more confident. Caitlyn, 20, North Carolina

I avoid black shirts. I have psoriasis on my scalp, so flakes are going to stand out on a black shirt. I stick to bright colors and patterns, and fabrics like satin or silk, where you can just flick off any flakes that fall down. Erin, 27, Ohio

*Quotes have been edited for length and clarity.

Read the original post:
10 Women Living With Psoriasis Share Their Confidence-Boosting Tips - Glamour

Psoriasis is a skin condition that has no cure, but with the correct knowledge, can be treated.

Psoriasis is a noncommunicable skin condition characterised by the appearance of red, flaky, crusty patches of skin that are covered with silvery scales.

In some cases these patches can be itchy and painful. Although psoriasis can appear anywhere on the body, the patches are most usually found on the elbows, knees, lower back and/or scalp.

Research suggests that psoriasis-causing changes in the skin originate from the immune system, whereby certain immune cells known as T cells are triggered and become overactive.

Debunking common myths on skin cancer

These cells begin reacting as they would if they were fighting an infection or healing a wound. This leads to the production of inflammatory chemicals in the body that, in turn, accelerate the growth of skin cells which causes these psoriatic patches or plaques to form.

This is why psoriasis is often described as an auto-immune disease. The exact trigger that offsets the immune system to react in this way remains unknown. While family history can be a reason for some, it is not the case for all.

Psoriasis flare-ups can be triggered by a number of external factors such as stress, hormonal changes, skin injuries, infections or certain medications.

According to the World Health Organization (WHO), psoriasis affects people of all ages worldwide. At least 100 million people are affected globally, with prevalence ranging from 0.09 and 11.43% depending on the country.

Read also: World Breastfeeding Week: the benefits for mum

Psoriasis can have a number of triggers and is often associated with significant comorbidities such as cardiovascular disease, arthritis, inflammatory bowel disease, metabolic syndrome, and depression.

In order to diagnose psoriasis, the examining physician may ask questions about your health, your scalp, skin and nails. The doctor may also take a sample of skin (biopsy) to examine under the microscope to help determine the exact type of psoriasis and rule out other disorders.

Although there is no cure for psoriasis, there are treatments that can help to ease the symptoms. These treatments aim to stop the skin cells from growing quickly and remove scales. Different options for treatment include creams, ointments, light therapy (phototherapy), and oral or injected medications.

At times, you will have to try different drugs, or a combination of the different treatments to find out exactly what works for you and your case. What you are prescribed depends on the severity of the psoriasis, and how responsive it has been to treatments in the past.

Psoriasis Awareness Month (PAM) aims to unite people all over the world who are living with the condition during the month of August to support each other, raise public awareness, and encourage the goal of finding a cure.

PAM provides the opportunity for individuals living with psoriasis to share their personal stories about their journey and hear about the experiences of others living with the condition.

Awareness is especially important as misconceptions about psoriasis, like other diseases, can lead to social stigma. For example, some people believe that psoriasis is contagious, and can be passed on through contact with the affected individual.

This can instil fear and encourage the avoidance of people who have the condition. Therefore, sharing the facts and debunking the myths surrounding the condition helps to create a more inclusive environment for those living with the chronic condition.

Read also: The truth and mistruths about ADHD

PAM also provides the opportunity to support scientific research efforts for psoriasis. Additional research can help reveal more about the skin disorder and help us move forward in our journey to finding a cure.

If you would like to get involved, you can play your part and help spread the word on psoriasis by sharing a personal story or verified facts and resources on your social media platforms using the following hashtags: #PsoriasisAwareness, #PsoriasisAwarenessMonth, #PsoriasisActionMonth.

Maha El Akoum, MPH, is a public health professional currently working as Head of Content at World Innovation Summit for Health [WISH].

Follow Doha News onTwitter,Instagram,FacebookandYoutube

Read the original:
What is psoriasis and what are its triggers? - Doha News

Psoriasis is a chronic, inflammatory skin condition that affects 2% of people in the UK and 73,000 people in Ireland. The skin disorder manifests as red, dry, and flaky patches of skin, which can appear anywhere, although the elbows, knees, scalp, and lower back are hotspots. The patches can also feel sore and itchy.

The scaly patches occur when skin cells are produced and shed abnormally fast. Usually, skin proliferation the process of skin cells reproducing and maturing takes 28 days.

However, with psoriasis, skin-cell proliferation has rapidly sped up and only takes three to seven days. This causes a build-up of dead cells on the surface of the skin, which results in the red, raised patches of skin, otherwise called plaque.

Its still unclear how big of a role genetics play in psoriasis, but youre more likely to suffer from the skin condition if one of your parents has it even more so if both of your parents do.

In fact, you have a 41% chance of developing psoriasis if both of your parents have it.

Psoriasis is an autoimmune skin condition. Its believed that the bodys immune system is involved in the development of psoriasis and its consequent flare-ups.

Put simply, its the immune systems job to defend us from infection and disease, but with psoriasis, the immune system accidentally attacks healthy skin cells.

Emotional stress, an infection, or certain medication can stimulate an abnormal immune response and the overproduction of skin cells, which results in dry, scaly patches.

Many sufferers find flare-ups of the skin condition emotionally debilitating, but targeted treatments can ease symptoms. The treatments cannot cure psoriasis, because its chronic, which means that it persists long-term or recurs frequently.

However, they can reduce inflammation and the appearance of dry patches.

Basic tips

Lets start with basic skincare tips. First off, try to be very gentle with your skin: That means refraining from scrubbing it, showering and bathing in warm water thats not boiling, and tapping your skin dry with a towel, instead of rubbing it.

Plus, skin can feel a little dry after showering, because of the humidity and warm water, so be sure to moisturise regularly to lock in hydration and keep any itchiness at bay.

Where treatments are concerned, your doctor might prescribe a topical cream or ointment that contains vitamin D analogues. Vitamin D diminishes dry patches by slowing down the rate that skin cells are being produced, which, in turn, reduces the amount of dead skin cells building up and patches from forming on the skin.

Corticosteroids are another type of topical treatment: Theyre steroids applied directly to the skin, which help to bring down inflammation and irritation.

The steroids come in four strengths, with the strongest formulation only available by prescription.

If topical treatments dont seem to work or if your condition is more severe, phototherapy can be used. The treatment involves exposing your skin to certain types of ultraviolet light.

The skin is an organ and should be treated as such. If you suspect youre suffering from psoriasis, I advise that you book an appointment with your doctor to discuss your symptoms.

Nerdie Pick

Theres no denying that clay masks feel like the ultimate pampering skincare product. This Environ Focus Care Comfort+ Anti-Pollution Masque is formulated to absorb the pollutant particles that can cause damage to the skin when left unattended.

It contains Japanese charcoal and kaolin clay to draw debris out of the skin, a potent antioxidant to protect the skin from free radical damage caused by pollution, and shea butter to hydrate the skin.

Use the mask one to three times a week for the best results. I like to apply a cherry-sized amount and leave it on for 20 minutes it's particularly great for oily-skinned people.

Environ Focus Care Comfort+ Anti-Pollution Masque (52, theskinnerd.com).

See original here:
The Skin Nerd: What exactly is psoriasis? - Irish Examiner

BRUSSELS, Belgium and ATLANTA, Aug. 7, 2021 /PRNewswire/ --UCB, a global biopharmaceutical company, announced today new interim data from BE BRIGHT, an open-label extension (OLE) trial to assess the long-term safety, tolerability and efficacy of bimekizumab, an investigational IL-17A and IL-17F inhibitor, in adults with moderate to severe plaque psoriasis.1,2These results were presented today during a platform presentation at the 2021 American Academy of Dermatology (AAD) Summer Meeting, Tampa, Florida, U.S.

Data presented showed that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to two years with continuous maintenance dosing, every four weeks (Q4W) or every eight weeks (Q8W).1The efficacy and safety of bimekizumab have not been established and it is not approved by any regulatory authority worldwide.

"These interim results from the BE BRIGHT study highlight the potential of bimekizumab to provide lasting skin clearance to adults living with moderate to severe plaque psoriasis," said Mark Lebwohl, MD, Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, and Chairman emeritus, Kimberly and Eric J. Waldman Department of Dermatologyand Presenting Author of the data at the AAD Summer Meeting. "These data are meaningful for the dermatology community and further add to the clinical evidence we have from the bimekizumab Phase 3 clinical program."

"Given the chronic nature of psoriasis, physicians and patients value treatment options that can offer long-term disease control," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB. "We are pleased to share the first presentation of bimekizumab data from the BE BRIGHT study highlighting the potential of bimekizumab to provide complete skin clearance that can last through to two years in adult patients with moderate to severe plaque psoriasis."

Results shared today report on the maintenance of the Investigator's Global Assessment (IGA) of Clear or Almost Clear skin (IGA 0/1), Body Surface Area (BSA) 1%, and Psoriasis Area and Severity Index (PASI) 100 through to two years of bimekizumab treatment.1Analyses included patients randomized to bimekizumab 320 mg Q4W who exhibited a response at week 16 in one of the pivotal Phase 3 studies (BE READY, BE VIVID, BE SURE), received bimekizumab 320 mg Q4W or Q8W maintenance dosing from week 16, and continued with the same maintenance dosing in the open-label BE BRIGHT study, i.e., Q4W/Q4W/Q4W or Q4W/Q8W/Q8W.1

Initially, 989 patients were randomized to bimekizumab Q4W. At week 16, 87.5 percent achieved IGA 0/1, 74.9 percent achieved BSA 1% and 62.7 percent achieved PASI 100. Among week 16 IGA 0/1 responders, over nine out of 10 patients maintained IGA 0/1 to week 48 in the OLE trial (94.4 and 96.2 percent with continuous Q4W and Q8W maintenance dosing, respectively).1Similarly, among week 16 BSA 1% responders, over nine out of 10 patients maintained BSA 1% to week 48 in the OLE trial (90.7 and 92.5 percent with continuous Q4W and Q8W maintenance dosing, respectively). Over eight out of 10 patients who achieved complete skin clearance (PASI 100) at week 16 maintained response to week 48 in the OLE trial (80.7 and 86.1 percent with continuous Q4W and Q8W maintenance dosing, respectively).1

In BE READY, BE VIVID and BE SURE, the most frequently reported treatment-emergent adverse events in bimekizumab-treated patients were nasopharyngitis, oral candidiasis, and upper respiratory tract infection.3,4,5,6

Bimekizumab is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults. On June 25th, 2021, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending granting a marketing authorization for bimekizumab for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. The final decision of the European Commission on marketing authorization is expected within approximately two months of the CHMP opinion.

About BE BRIGHT2BE BRIGHT (NCT03598790) is an ongoing, multicentre, open-label extension study assessing the long-term safety, tolerability and efficacy of bimekizumab in adult patients with moderate to severe plaque psoriasis. Patients who completed one of three bimekizumab Phase 3 studies, BE READY, BE VIVID and BE SURE, were eligible to enroll in the BE BRIGHT study. More details can be found at ClinicalTrials.gov.

About bimekizumab Bimekizumab is an investigational humanized IgG1 monoclonal antibody that is designed to selectively and directly inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes.4,5,6 Selective inhibition of IL-17F in addition to IL-17A has been shown to suppress inflammation to a greater extent than IL-17A inhibition alone.4,5,6

The efficacy and safety of bimekizumab have not been established and it is not approved by any regulatory authority worldwide.

AboutPsoriasisPsoriasis is a common, chronic inflammatory disease with primary involvement of the skin.7This skin condition affects men and women of all ages and ethnicities.7Psoriasis signs and symptoms can vary but may include red patches of skin covered with silvery scales; dry, cracked skin that may bleed; and thickened, pitted or ridged nails.8Psoriasis also has a considerable psychological and quality-of-life impact, potentially affecting work, recreation, relationships, sexual functioning, family and social life.9

Unmet needs remain in the treatment of psoriasis. A population-based survey identified that approximately one in three psoriasis patients reported that their primary goals of therapy, including keeping symptoms under control, reducing itching and decreasing flaking, were not met with their current treatment.10

About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,400 people in nearly 40 countries, the company generated revenue of 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Forward looking statements UCB This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB' efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

For further information, contact UCB:

Corporate Communications

Laurent Schots,

Media Relations, UCB

T +32.2.559.92.64

[emailprotected]

Investor Relations

Antje Witte,

Investor Relations, UCB

T +32.2.559.94.14

[emailprotected]

Brand Communications

Eimear O'Brien,

Brand Communications, UCB

T +32.2.559.92.71

[emailprotected]

Allyson FunkU.S. Communications, UCBT +1 770 970 8338[emailprotected]

References

1

Strober B, Asahina A, Mrowietz U, et al. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. Abstract presented at AAD Summer 2021

2

ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT03598790Last accessed: August 2021.

3

UCB Data on File, July 2021.

4

Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial. Lancet.2021;397(10273):487-498.

5

Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475-486.

6

Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021;385(2):130-141.

7

National Psoriasis Foundation. About Psoriasis. Available at: https://www.psoriasis.org/about-psoriasis/. Last accessed: August2021.

8

International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/our-cause.Last accessed: August2021.

9

Moon HS, Mizara A, McBride SR. Psoriasis and psycho-dermatology. Dermatol Ther (Heidelb). 2013;3(2):117-130.

10

Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016;17(1):87-97.

SOURCE UCB

http://www.ucb.com

Go here to read the rest:
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis - PRNewswire